NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 82 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $11,929 | +18.6% | 14,372 | 0.0% | 0.00% | – |
| Q1 2023 | $10,060 | +37.5% | 14,372 | 0.0% | 0.00% | – |
| Q4 2022 | $7,315 | -18.7% | 14,372 | 0.0% | 0.00% | – |
| Q3 2022 | $9,000 | -40.0% | 14,372 | -0.6% | 0.00% | – |
| Q2 2022 | $15,000 | -93.1% | 14,457 | -87.5% | 0.00% | – |
| Q1 2022 | $218,000 | -61.8% | 116,026 | -1.8% | 0.00% | – |
| Q4 2021 | $570,000 | -35.7% | 118,152 | -3.8% | 0.00% | – |
| Q3 2021 | $887,000 | -16.6% | 122,766 | +6.6% | 0.00% | – |
| Q2 2021 | $1,063,000 | -25.4% | 115,142 | -0.5% | 0.00% | – |
| Q1 2021 | $1,425,000 | -15.2% | 115,747 | -3.0% | 0.00% | – |
| Q4 2020 | $1,681,000 | +25.8% | 119,275 | +7.1% | 0.00% | – |
| Q3 2020 | $1,336,000 | -31.5% | 111,347 | -5.2% | 0.00% | -100.0% |
| Q2 2020 | $1,950,000 | +652.9% | 117,497 | +415.9% | 0.00% | – |
| Q1 2020 | $259,000 | +32.8% | 22,775 | +43.5% | 0.00% | – |
| Q4 2019 | $195,000 | +314.9% | 15,866 | -3.7% | 0.00% | – |
| Q3 2019 | $47,000 | – | 16,478 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,047,300 | $5,048,000 | 1.07% |
| ACT CAPITAL MANAGEMENT, LLC | 212,500 | $1,024,000 | 0.74% |
| Redmile Group, LLC | 3,490,835 | $16,826,000 | 0.38% |
| Kynam Capital Management, LP | 147,000 | $709,000 | 0.38% |
| EcoR1 Capital, LLC | 860,619 | $4,148,000 | 0.13% |
| Baker Brothers Advisors | 3,821,740 | $18,421,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 130,899 | $631,000 | 0.08% |
| Sio Capital Management, LLC | 38,312 | $185,000 | 0.06% |
| Highland Private Wealth Management | 46,999 | $227,000 | 0.03% |
| XTX Topco Ltd | 10,018 | $48,000 | 0.03% |